

# Global Biologics and Biosimilars Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G291750DC07AEN.html>

Date: January 2026

Pages: 134

Price: US\$ 4,480.00 (Single User License)

ID: G291750DC07AEN

## Abstracts

The global Biologics and Biosimilars market size is expected to reach \$ 859990 million by 2032, rising at a market growth of 8.5% CAGR during the forecast period (2026-2032).

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products. A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original 'innovator' products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval. The average gross profit margin of this product is 76%.

The growth of the biologics and biosimilars market is driven by the rise of precision medicine, increasing prevalence of chronic and rare diseases, and the demand for cost-effective therapies. Advances in genetic engineering, cell culture, protein expression, and delivery systems have accelerated the development of next-generation antibodies and fusion proteins. Meanwhile, the establishment of harmonized biosimilar regulatory pathways worldwide provides new opportunities for emerging companies and markets. Government incentives supporting innovation and generic substitution further fuel market expansion and diversification.

The key challenges in this field include high manufacturing complexity, difficulty in ensuring batch-to-batch consistency, and regulatory heterogeneity across global markets. Biologics development requires significant time and investment, with stringent

standards for cold chain logistics and process validation. Although biosimilars offer lower costs, their adoption is still influenced by physician perception, brand loyalty, and reimbursement systems. Frequent intellectual property disputes, extended patent exclusivity, and technological barriers further restrict new entrants and limit market competitiveness. Downstream demand is shifting toward personalized and long-term therapies. Demand for biologics continues to rise in oncology, autoimmune disorders, diabetes, and inflammatory diseases, particularly for targeted and immune-modulating biologics. As healthcare reimbursement systems evolve and coverage expands, biosimilar adoption is rapidly increasing in emerging markets. The proliferation of hospital pharmacies, specialty clinics, and at-home injectable treatments is also driving growth in long-acting and user-friendly formulations.

The upstream supply chain for biologics and biosimilars relies heavily on high-purity cell culture media, serum substitutes, recombinant enzymes, buffers, and advanced filtration consumables. Consistent raw material quality and robust supply chains are vital for production reliability. The adoption of recombinant human serum albumin (rHSA), animal-free culture systems, and high-performance bioreactors has significantly reduced batch variability and enhanced efficiency. Automation and digitalization of upstream processes are emerging as key enablers of competitiveness in the biologics manufacturing ecosystem.

This report studies the global Biologics and Biosimilars demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Biologics and Biosimilars, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Biologics and Biosimilars that contribute to its increasing demand across many markets.

### **Highlights and key features of the study**

Global Biologics and Biosimilars total market, 2021-2032, (USD Million)

Global Biologics and Biosimilars total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Biologics and Biosimilars total market, key domestic companies, and share, (USD Million)

Global Biologics and Biosimilars revenue by player, revenue and market share 2021-2026, (USD Million)

Global Biologics and Biosimilars total market by Type, CAGR, 2021-2032, (USD Million)

Global Biologics and Biosimilars total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Biologics and Biosimilars market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Biologics and Biosimilars market

### **Detailed Segmentation:**

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Biologics and Biosimilars Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

## Global Biologics and Biosimilars Market, Segmentation by Type:

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Others

## Global Biologics and Biosimilars Market, Segmentation by Therapeutic Area:

Oncology

Autoimmune Diseases

Endocrinology & Diabetes

Hematology

Other

## Global Biologics and Biosimilars Market, Segmentation by Route of Administration:

Injectable

Inhalable Formulations

Oral Biologics

## Global Biologics and Biosimilars Market, Segmentation by Application:

Hospital

Retail Pharmacy

Other

Companies Profiled:

Roche

Amgen

AbbVie

Sanofi

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

Biogen

Celltrion

Sobi

3SBIO

Changchun High Tech

Kanghong Pharma

Innovent Biologics

Gan&Lee

Tonghua Dongbao

United Laboratory

### **Key Questions Answered**

1. How big is the global Biologics and Biosimilars market?
2. What is the demand of the global Biologics and Biosimilars market?
3. What is the year over year growth of the global Biologics and Biosimilars market?
4. What is the total value of the global Biologics and Biosimilars market?
5. Who are the Major Players in the global Biologics and Biosimilars market?
6. What are the growth factors driving the market demand?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 SCADA Introduction
- 1.2 World SCADA Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World SCADA Total Market by Region (by Headquarter Location)
  - 1.3.1 World SCADA Market Size by Region (2021-2032), (by Headquarter Location)
  - 1.3.2 United States Based Company SCADA Revenue (2021-2032)
  - 1.3.3 China Based Company SCADA Revenue (2021-2032)
  - 1.3.4 Europe Based Company SCADA Revenue (2021-2032)
  - 1.3.5 Japan Based Company SCADA Revenue (2021-2032)
  - 1.3.6 South Korea Based Company SCADA Revenue (2021-2032)
  - 1.3.7 ASEAN Based Company SCADA Revenue (2021-2032)
  - 1.3.8 India Based Company SCADA Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 SCADA Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Major Market Trends

### 2 DEMAND SUMMARY

- 2.1 World SCADA Consumption Value (2021-2032)
- 2.2 World SCADA Consumption Value by Region
  - 2.2.1 World SCADA Consumption Value by Region (2021-2026)
  - 2.2.2 World SCADA Consumption Value Forecast by Region (2027-2032)
- 2.3 United States SCADA Consumption Value (2021-2032)
- 2.4 China SCADA Consumption Value (2021-2032)
- 2.5 Europe SCADA Consumption Value (2021-2032)
- 2.6 Japan SCADA Consumption Value (2021-2032)
- 2.7 South Korea SCADA Consumption Value (2021-2032)
- 2.8 ASEAN SCADA Consumption Value (2021-2032)
- 2.9 India SCADA Consumption Value (2021-2032)

### 3 WORLD SCADA COMPANIES COMPETITIVE ANALYSIS

- 3.1 World SCADA Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)
  - 3.2.1 Global SCADA Industry Rank of Major Players

- 3.2.2 Global Concentration Ratios (CR4) for SCADA in 2025
- 3.2.3 Global Concentration Ratios (CR8) for SCADA in 2025
- 3.3 SCADA Company Evaluation Quadrant
- 3.4 SCADA Market: Overall Company Footprint Analysis
  - 3.4.1 SCADA Market: Region Footprint
  - 3.4.2 SCADA Market: Company Product Type Footprint
  - 3.4.3 SCADA Market: Company Product Application Footprint
- 3.5 Competitive Environment
  - 3.5.1 Historical Structure of the Industry
  - 3.5.2 Barriers of Market Entry
  - 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

## **4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)**

- 4.1 United States VS China: SCADA Revenue Comparison (by Headquarter Location)
  - 4.1.1 United States VS China: SCADA Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
  - 4.1.2 United States VS China: SCADA Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: SCADA Consumption Value Comparison
  - 4.2.1 United States VS China: SCADA Consumption Value Comparison (2021 & 2025 & 2032)
  - 4.2.2 United States VS China: SCADA Consumption Value Market Share Comparison (2021 & 2025 & 2032)
- 4.3 United States Based SCADA Companies and Market Share, 2021-2026
  - 4.3.1 United States Based SCADA Companies, Headquarters (States, Country)
  - 4.3.2 United States Based Companies SCADA Revenue, (2021-2026)
- 4.4 China Based Companies SCADA Revenue and Market Share, 2021-2026
  - 4.4.1 China Based SCADA Companies, Company Headquarters (Province, Country)
  - 4.4.2 China Based Companies SCADA Revenue, (2021-2026)
- 4.5 Rest of World Based SCADA Companies and Market Share, 2021-2026
  - 4.5.1 Rest of World Based SCADA Companies, Headquarters (Province, Country)
  - 4.5.2 Rest of World Based Companies SCADA Revenue (2021-2026)

## **5 MARKET ANALYSIS BY TYPE**

## 5.1 World SCADA Market Size Overview by Type: 2021 VS 2025 VS 2032

### 5.2 Segment Introduction by Type

#### 5.2.1 Hardware

#### 5.2.2 Software

#### 5.2.3 Services

### 5.3 Market Segment by Type

#### 5.3.1 World SCADA Market Size by Type (2021-2026)

#### 5.3.2 World SCADA Market Size by Type (2027-2032)

#### 5.3.3 World SCADA Market Size Market Share by Type (2027-2032)

## 6 MARKET ANALYSIS BY APPLICATION

### 6.1 World SCADA Market Size Overview by Application: 2021 VS 2025 VS 2032

#### 6.2 Segment Introduction by Application

##### 6.2.1 Power & Energy

##### 6.2.2 Oil & Gas Industry

##### 6.2.3 Water & Waste Control

##### 6.2.4 Telecommunications

##### 6.2.5 Transportation

##### 6.2.6 Manufacturing Industry

##### 6.2.7 Others

#### 6.3 Market Segment by Application

##### 6.3.1 World SCADA Market Size by Application (2021-2026)

##### 6.3.2 World SCADA Market Size by Application (2027-2032)

##### 6.3.3 World SCADA Market Size Market Share by Application (2021-2032)

## 7 COMPANY PROFILES

### 7.1 Schneider Electric SE (France)

#### 7.1.1 Schneider Electric SE (France) Details

#### 7.1.2 Schneider Electric SE (France) Major Business

#### 7.1.3 Schneider Electric SE (France) SCADA Product and Services

#### 7.1.4 Schneider Electric SE (France) SCADA Revenue, Gross Margin and Market Share (2021-2026)

#### 7.1.5 Schneider Electric SE (France) Recent Developments/Updates

#### 7.1.6 Schneider Electric SE (France) Competitive Strengths & Weaknesses

### 7.2 ABB (Switzerland)

#### 7.2.1 ABB (Switzerland) Details

#### 7.2.2 ABB (Switzerland) Major Business

- 7.2.3 ABB (Switzerland) SCADA Product and Services
- 7.2.4 ABB (Switzerland) SCADA Revenue, Gross Margin and Market Share (2021-2026)
- 7.2.5 ABB (Switzerland) Recent Developments/Updates
- 7.2.6 ABB (Switzerland) Competitive Strengths & Weaknesses
- 7.3 Siemens AG (Germany)
- 7.3.1 Siemens AG (Germany) Details
- 7.3.2 Siemens AG (Germany) Major Business
- 7.3.3 Siemens AG (Germany) SCADA Product and Services
- 7.3.4 Siemens AG (Germany) SCADA Revenue, Gross Margin and Market Share (2021-2026)
- 7.3.5 Siemens AG (Germany) Recent Developments/Updates
- 7.3.6 Siemens AG (Germany) Competitive Strengths & Weaknesses
- 7.4 Emerson (US)
- 7.4.1 Emerson (US) Details
- 7.4.2 Emerson (US) Major Business
- 7.4.3 Emerson (US) SCADA Product and Services
- 7.4.4 Emerson (US) SCADA Revenue, Gross Margin and Market Share (2021-2026)
- 7.4.5 Emerson (US) Recent Developments/Updates
- 7.4.6 Emerson (US) Competitive Strengths & Weaknesses
- 7.5 Rockwell Automation Inc. (US)
- 7.5.1 Rockwell Automation Inc. (US) Details
- 7.5.2 Rockwell Automation Inc. (US) Major Business
- 7.5.3 Rockwell Automation Inc. (US) SCADA Product and Services
- 7.5.4 Rockwell Automation Inc. (US) SCADA Revenue, Gross Margin and Market Share (2021-2026)
- 7.5.5 Rockwell Automation Inc. (US) Recent Developments/Updates
- 7.5.6 Rockwell Automation Inc. (US) Competitive Strengths & Weaknesses
- 7.6 Honeywell International Inc. (US)
- 7.6.1 Honeywell International Inc. (US) Details
- 7.6.2 Honeywell International Inc. (US) Major Business
- 7.6.3 Honeywell International Inc. (US) SCADA Product and Services
- 7.6.4 Honeywell International Inc. (US) SCADA Revenue, Gross Margin and Market Share (2021-2026)
- 7.6.5 Honeywell International Inc. (US) Recent Developments/Updates
- 7.6.6 Honeywell International Inc. (US) Competitive Strengths & Weaknesses
- 7.7 Mitsubishi Electric (Japan)
- 7.7.1 Mitsubishi Electric (Japan) Details
- 7.7.2 Mitsubishi Electric (Japan) Major Business

- 7.7.3 Mitsubishi Electric (Japan) SCADA Product and Services
- 7.7.4 Mitsubishi Electric (Japan) SCADA Revenue, Gross Margin and Market Share (2021-2026)
- 7.7.5 Mitsubishi Electric (Japan) Recent Developments/Updates
- 7.7.6 Mitsubishi Electric (Japan) Competitive Strengths & Weaknesses
- 7.8 Omron Corporation (Japan)
  - 7.8.1 Omron Corporation (Japan) Details
  - 7.8.2 Omron Corporation (Japan) Major Business
  - 7.8.3 Omron Corporation (Japan) SCADA Product and Services
  - 7.8.4 Omron Corporation (Japan) SCADA Revenue, Gross Margin and Market Share (2021-2026)
  - 7.8.5 Omron Corporation (Japan) Recent Developments/Updates
  - 7.8.6 Omron Corporation (Japan) Competitive Strengths & Weaknesses
- 7.9 General Electric Co. (US)
  - 7.9.1 General Electric Co. (US) Details
  - 7.9.2 General Electric Co. (US) Major Business
  - 7.9.3 General Electric Co. (US) SCADA Product and Services
  - 7.9.4 General Electric Co. (US) SCADA Revenue, Gross Margin and Market Share (2021-2026)
  - 7.9.5 General Electric Co. (US) Recent Developments/Updates
  - 7.9.6 General Electric Co. (US) Competitive Strengths & Weaknesses
- 7.10 Yokogawa Electric Corporation (Japan)
  - 7.10.1 Yokogawa Electric Corporation (Japan) Details
  - 7.10.2 Yokogawa Electric Corporation (Japan) Major Business
  - 7.10.3 Yokogawa Electric Corporation (Japan) SCADA Product and Services
  - 7.10.4 Yokogawa Electric Corporation (Japan) SCADA Revenue, Gross Margin and Market Share (2021-2026)
  - 7.10.5 Yokogawa Electric Corporation (Japan) Recent Developments/Updates
  - 7.10.6 Yokogawa Electric Corporation (Japan) Competitive Strengths & Weaknesses
- 7.11 Larsen & Toubro (India)
  - 7.11.1 Larsen & Toubro (India) Details
  - 7.11.2 Larsen & Toubro (India) Major Business
  - 7.11.3 Larsen & Toubro (India) SCADA Product and Services
  - 7.11.4 Larsen & Toubro (India) SCADA Revenue, Gross Margin and Market Share (2021-2026)
  - 7.11.5 Larsen & Toubro (India) Recent Developments/Updates
  - 7.11.6 Larsen & Toubro (India) Competitive Strengths & Weaknesses
- 7.12 M.B. Control & Systems Pvt. Ltd (India)
  - 7.12.1 M.B. Control & Systems Pvt. Ltd (India) Details

- 7.12.2 M.B. Control & Systems Pvt. Ltd (India) Major Business
- 7.12.3 M.B. Control & Systems Pvt. Ltd (India) SCADA Product and Services
- 7.12.4 M.B. Control & Systems Pvt. Ltd (India) SCADA Revenue, Gross Margin and Market Share (2021-2026)
- 7.12.5 M.B. Control & Systems Pvt. Ltd (India) Recent Developments/Updates
- 7.12.6 M.B. Control & Systems Pvt. Ltd (India) Competitive Strengths & Weaknesses

## **8 INDUSTRY CHAIN ANALYSIS**

- 8.1 SCADA Industry Chain
- 8.2 SCADA Upstream Analysis
- 8.3 SCADA Midstream Analysis
- 8.4 SCADA Downstream Analysis

## **9 RESEARCH FINDINGS AND CONCLUSION**

## **10 APPENDIX**

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. World Biologics and Biosimilars Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World Biologics and Biosimilars Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World Biologics and Biosimilars Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World Biologics and Biosimilars Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World Biologics and Biosimilars Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Biologics and Biosimilars Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World Biologics and Biosimilars Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World Biologics and Biosimilars Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World Biologics and Biosimilars Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key Biologics and Biosimilars Players in 2025

Table 12. World Biologics and Biosimilars Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global Biologics and Biosimilars Company Evaluation Quadrant

Table 14. Head Office of Key Biologics and Biosimilars Players

Table 15. Biologics and Biosimilars Market: Company Product Type Footprint

Table 16. Biologics and Biosimilars Market: Company Product Application Footprint

Table 17. Biologics and Biosimilars Mergers & Acquisitions Activity

Table 18. United States VS China Biologics and Biosimilars Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China Biologics and Biosimilars Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based Biologics and Biosimilars Companies, Headquarters (States, Country)

Table 21. United States Based Companies Biologics and Biosimilars Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies Biologics and Biosimilars Revenue Market Share (2021-2026)

Table 23. China Based Biologics and Biosimilars Companies, Headquarters (Province, Country)

Table 24. China Based Companies Biologics and Biosimilars Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies Biologics and Biosimilars Revenue Market Share (2021-2026)

Table 26. Rest of World Based Biologics and Biosimilars Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies Biologics and Biosimilars Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies Biologics and Biosimilars Revenue Market Share (2021-2026)

Table 29. World Biologics and Biosimilars Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World Biologics and Biosimilars Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World Biologics and Biosimilars Market Size by Type (2027-2032) & (USD Million)

Table 32. World Biologics and Biosimilars Market Size by Therapeutic Area, (USD Million), 2021 & 2025 & 2032

Table 33. World Biologics and Biosimilars Market Size Value by Therapeutic Area (2021-2026) & (USD Million)

Table 34. World Biologics and Biosimilars Market Size by Therapeutic Area (2027-2032) & (USD Million)

Table 35. World Biologics and Biosimilars Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032

Table 36. World Biologics and Biosimilars Market Size Value by Route of Administration (2021-2026) & (USD Million)

Table 37. World Biologics and Biosimilars Market Size by Route of Administration (2027-2032) & (USD Million)

Table 38. World Biologics and Biosimilars Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 39. World Biologics and Biosimilars Market Size by Application (2021-2026) & (USD Million)

Table 40. World Biologics and Biosimilars Market Size by Application (2027-2032) & (USD Million)

Table 41. Roche Basic Information, Manufacturing Base and Competitors

- Table 42. Roche Major Business
- Table 43. Roche Biologics and Biosimilars Product and Services
- Table 44. Roche Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 45. Roche Recent Developments/Updates
- Table 46. Roche Competitive Strengths & Weaknesses
- Table 47. Amgen Basic Information, Manufacturing Base and Competitors
- Table 48. Amgen Major Business
- Table 49. Amgen Biologics and Biosimilars Product and Services
- Table 50. Amgen Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 51. Amgen Recent Developments/Updates
- Table 52. Amgen Competitive Strengths & Weaknesses
- Table 53. AbbVie Basic Information, Manufacturing Base and Competitors
- Table 54. AbbVie Major Business
- Table 55. AbbVie Biologics and Biosimilars Product and Services
- Table 56. AbbVie Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 57. AbbVie Recent Developments/Updates
- Table 58. AbbVie Competitive Strengths & Weaknesses
- Table 59. Sanofi Basic Information, Manufacturing Base and Competitors
- Table 60. Sanofi Major Business
- Table 61. Sanofi Biologics and Biosimilars Product and Services
- Table 62. Sanofi Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 63. Sanofi Recent Developments/Updates
- Table 64. Sanofi Competitive Strengths & Weaknesses
- Table 65. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
- Table 66. Johnson & Johnson Major Business
- Table 67. Johnson & Johnson Biologics and Biosimilars Product and Services
- Table 68. Johnson & Johnson Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 69. Johnson & Johnson Recent Developments/Updates
- Table 70. Johnson & Johnson Competitive Strengths & Weaknesses
- Table 71. Pfizer Basic Information, Manufacturing Base and Competitors
- Table 72. Pfizer Major Business
- Table 73. Pfizer Biologics and Biosimilars Product and Services
- Table 74. Pfizer Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

- Table 75. Pfizer Recent Developments/Updates
- Table 76. Pfizer Competitive Strengths & Weaknesses
- Table 77. Novo Nordisk Basic Information, Manufacturing Base and Competitors
- Table 78. Novo Nordisk Major Business
- Table 79. Novo Nordisk Biologics and Biosimilars Product and Services
- Table 80. Novo Nordisk Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 81. Novo Nordisk Recent Developments/Updates
- Table 82. Novo Nordisk Competitive Strengths & Weaknesses
- Table 83. Eli Lilly Basic Information, Manufacturing Base and Competitors
- Table 84. Eli Lilly Major Business
- Table 85. Eli Lilly Biologics and Biosimilars Product and Services
- Table 86. Eli Lilly Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 87. Eli Lilly Recent Developments/Updates
- Table 88. Eli Lilly Competitive Strengths & Weaknesses
- Table 89. Novartis Basic Information, Manufacturing Base and Competitors
- Table 90. Novartis Major Business
- Table 91. Novartis Biologics and Biosimilars Product and Services
- Table 92. Novartis Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 93. Novartis Recent Developments/Updates
- Table 94. Novartis Competitive Strengths & Weaknesses
- Table 95. Merck Basic Information, Manufacturing Base and Competitors
- Table 96. Merck Major Business
- Table 97. Merck Biologics and Biosimilars Product and Services
- Table 98. Merck Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 99. Merck Recent Developments/Updates
- Table 100. Merck Competitive Strengths & Weaknesses
- Table 101. Biogen Basic Information, Manufacturing Base and Competitors
- Table 102. Biogen Major Business
- Table 103. Biogen Biologics and Biosimilars Product and Services
- Table 104. Biogen Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 105. Biogen Recent Developments/Updates
- Table 106. Biogen Competitive Strengths & Weaknesses
- Table 107. Celltrion Basic Information, Manufacturing Base and Competitors
- Table 108. Celltrion Major Business

- Table 109. Celltrion Biologics and Biosimilars Product and Services
- Table 110. Celltrion Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 111. Celltrion Recent Developments/Updates
- Table 112. Celltrion Competitive Strengths & Weaknesses
- Table 113. Sobi Basic Information, Manufacturing Base and Competitors
- Table 114. Sobi Major Business
- Table 115. Sobi Biologics and Biosimilars Product and Services
- Table 116. Sobi Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 117. Sobi Recent Developments/Updates
- Table 118. Sobi Competitive Strengths & Weaknesses
- Table 119. 3SBIO Basic Information, Manufacturing Base and Competitors
- Table 120. 3SBIO Major Business
- Table 121. 3SBIO Biologics and Biosimilars Product and Services
- Table 122. 3SBIO Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 123. 3SBIO Recent Developments/Updates
- Table 124. 3SBIO Competitive Strengths & Weaknesses
- Table 125. Changchun High Tech Basic Information, Manufacturing Base and Competitors
- Table 126. Changchun High Tech Major Business
- Table 127. Changchun High Tech Biologics and Biosimilars Product and Services
- Table 128. Changchun High Tech Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 129. Changchun High Tech Recent Developments/Updates
- Table 130. Changchun High Tech Competitive Strengths & Weaknesses
- Table 131. Kanghong Pharma Basic Information, Manufacturing Base and Competitors
- Table 132. Kanghong Pharma Major Business
- Table 133. Kanghong Pharma Biologics and Biosimilars Product and Services
- Table 134. Kanghong Pharma Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 135. Kanghong Pharma Recent Developments/Updates
- Table 136. Kanghong Pharma Competitive Strengths & Weaknesses
- Table 137. Innovent Biologics Basic Information, Manufacturing Base and Competitors
- Table 138. Innovent Biologics Major Business
- Table 139. Innovent Biologics Biologics and Biosimilars Product and Services
- Table 140. Innovent Biologics Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

- Table 141. Innovent Biologics Recent Developments/Updates
- Table 142. Innovent Biologics Competitive Strengths & Weaknesses
- Table 143. Gan&Lee Basic Information, Manufacturing Base and Competitors
- Table 144. Gan&Lee Major Business
- Table 145. Gan&Lee Biologics and Biosimilars Product and Services
- Table 146. Gan&Lee Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 147. Gan&Lee Recent Developments/Updates
- Table 148. Gan&Lee Competitive Strengths & Weaknesses
- Table 149. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
- Table 150. Tonghua Dongbao Major Business
- Table 151. Tonghua Dongbao Biologics and Biosimilars Product and Services
- Table 152. Tonghua Dongbao Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 153. Tonghua Dongbao Recent Developments/Updates
- Table 154. Tonghua Dongbao Competitive Strengths & Weaknesses
- Table 155. United Laboratory Basic Information, Manufacturing Base and Competitors
- Table 156. United Laboratory Major Business
- Table 157. United Laboratory Biologics and Biosimilars Product and Services
- Table 158. United Laboratory Biologics and Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 159. United Laboratory Recent Developments/Updates
- Table 160. United Laboratory Competitive Strengths & Weaknesses
- Table 161. Global Key Players of Biologics and Biosimilars Upstream (Raw Materials)
- Table 162. Global Biologics and Biosimilars Typical Customers

## List Of Figures

### LIST OF FIGURES

- Figure 1. Biologics and Biosimilars Picture
- Figure 2. World Biologics and Biosimilars Total Revenue: 2021 & 2025 & 2032, (USD Million)
- Figure 3. World Biologics and Biosimilars Total Revenue (2021-2032) & (USD Million)
- Figure 4. World Biologics and Biosimilars Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
- Figure 5. World Biologics and Biosimilars Revenue Market Share by Region (2021-2032), (by Headquarter Location)
- Figure 6. United States Based Company Biologics and Biosimilars Revenue (2021-2032) & (USD Million)
- Figure 7. China Based Company Biologics and Biosimilars Revenue (2021-2032) & (USD Million)
- Figure 8. Europe Based Company Biologics and Biosimilars Revenue (2021-2032) & (USD Million)
- Figure 9. Japan Based Company Biologics and Biosimilars Revenue (2021-2032) & (USD Million)
- Figure 10. South Korea Based Company Biologics and Biosimilars Revenue (2021-2032) & (USD Million)
- Figure 11. ASEAN Based Company Biologics and Biosimilars Revenue (2021-2032) & (USD Million)
- Figure 12. India Based Company Biologics and Biosimilars Revenue (2021-2032) & (USD Million)
- Figure 13. Biologics and Biosimilars Market Drivers
- Figure 14. Factors Affecting Demand
- Figure 15. World Biologics and Biosimilars Consumption Value (2021-2032) & (USD Million)
- Figure 16. World Biologics and Biosimilars Consumption Value Market Share by Region (2021-2032)
- Figure 17. United States Biologics and Biosimilars Consumption Value (2021-2032) & (USD Million)
- Figure 18. China Biologics and Biosimilars Consumption Value (2021-2032) & (USD Million)
- Figure 19. Europe Biologics and Biosimilars Consumption Value (2021-2032) & (USD Million)
- Figure 20. Japan Biologics and Biosimilars Consumption Value (2021-2032) & (USD Million)

Million)

Figure 21. South Korea Biologics and Biosimilars Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN Biologics and Biosimilars Consumption Value (2021-2032) & (USD Million)

Figure 23. India Biologics and Biosimilars Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of Biologics and Biosimilars by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for Biologics and Biosimilars Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for Biologics and Biosimilars Markets in 2025

Figure 27. United States VS China: Biologics and Biosimilars Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: Biologics and Biosimilars Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World Biologics and Biosimilars Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World Biologics and Biosimilars Market Size Market Share by Type in 2025

Figure 31. Monoclonal Antibodies

Figure 32. Interferon

Figure 33. Insulin

Figure 34. Vaccines

Figure 35. Others

Figure 36. World Biologics and Biosimilars Market Size Market Share by Type (2021-2032)

Figure 37. World Biologics and Biosimilars Market Size by Therapeutic Area, (USD Million), 2021 & 2025 & 2032

Figure 38. World Biologics and Biosimilars Market Size Market Share by Therapeutic Area in 2025

Figure 39. Oncology

Figure 40. Autoimmune Diseases

Figure 41. Endocrinology & Diabetes

Figure 42. Hematology

Figure 43. Other

Figure 44. World Biologics and Biosimilars Market Size Market Share by Therapeutic Area (2021-2032)

Figure 45. World Biologics and Biosimilars Market Size by Route of Administration,

(USD Million), 2021 & 2025 & 2032

Figure 46. World Biologics and Biosimilars Market Size Market Share by Route of Administration in 2025

Figure 47. Injectable

Figure 48. Inhalable Formulations

Figure 49. Oral Biologics

Figure 50. World Biologics and Biosimilars Market Size Market Share by Route of Administration (2021-2032)

Figure 51. World Biologics and Biosimilars Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 52. World Biologics and Biosimilars Market Size Market Share by Application in 2025

Figure 53. Hospital

Figure 54. Retail Pharmacy

Figure 55. Other

Figure 56. World Biologics and Biosimilars Market Size Market Share by Application (2021-2032)

Figure 57. Biologics and Biosimilars Industrial Chain

Figure 58. Methodology

Figure 59. Research Process and Data Source

## I would like to order

Product name: Global Biologics and Biosimilars Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G291750DC07AEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G291750DC07AEN.html>